- Home
- CZR vs BLTE Comparison
CZR vs BLTE Comparison
Compare CZR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZR
- BLTE
- Stock Information
- Founded
- CZR 1937
- BLTE 2018
- Country
- CZR United States
- BLTE United States
- Employees
- CZR N/A
- BLTE N/A
- Industry
- CZR Hotels/Resorts
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- CZR Consumer Discretionary
- BLTE Health Care
- Exchange
- CZR Nasdaq
- BLTE Nasdaq
- Market Cap
- CZR 4.4B
- BLTE 4.1B
- IPO Year
- CZR 1989
- BLTE 2022
- Fundamental
- Price
- CZR $20.95
- BLTE $135.99
- Analyst Decision
- CZR Buy
- BLTE Strong Buy
- Analyst Count
- CZR 16
- BLTE 6
- Target Price
- CZR $35.88
- BLTE $113.80
- AVG Volume (30 Days)
- CZR 11.2M
- BLTE 126.6K
- Earning Date
- CZR 10-28-2025
- BLTE 11-10-2025
- Dividend Yield
- CZR N/A
- BLTE N/A
- EPS Growth
- CZR N/A
- BLTE N/A
- EPS
- CZR N/A
- BLTE N/A
- Revenue
- CZR $11,369,000,000.00
- BLTE N/A
- Revenue This Year
- CZR $3.17
- BLTE N/A
- Revenue Next Year
- CZR $2.85
- BLTE N/A
- P/E Ratio
- CZR N/A
- BLTE N/A
- Revenue Growth
- CZR 0.87
- BLTE N/A
- 52 Week Low
- CZR $18.25
- BLTE $49.00
- 52 Week High
- CZR $40.00
- BLTE $143.79
- Technical
- Relative Strength Index (RSI)
- CZR 49.59
- BLTE 71.00
- Support Level
- CZR $19.75
- BLTE $105.88
- Resistance Level
- CZR $20.78
- BLTE $125.24
- Average True Range (ATR)
- CZR 0.99
- BLTE 9.27
- MACD
- CZR 0.31
- BLTE 0.51
- Stochastic Oscillator
- CZR 79.09
- BLTE 76.92
About CZR Caesars Entertainment Inc.
Caesars Entertainment includes about 50 domestic gaming properties across the Las Vegas (49% of 2024 EBITDAR before corporate expenses) and regional (46%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2024. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.